This inventor holds 3 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents. Top assignees: Genethon, Association Institut De Myologie, Centre National De La Recherche Scientifique. Active years: 2017-2021.
Company Filing History:
3 out of 59 
1 out of 24 
1 out of 5,383 
Years Active: 2017-2021
Title: Fedor Svinartchouk: Innovator in Muscular Dystrophy Diagnosis
Introduction
Fedor Svinartchouk is a notable inventor based in Villejuif, France. He has made significant contributions to the field of medical diagnostics, particularly in relation to muscular dystrophies. With a total of 3 patents, his work focuses on innovative methods for diagnosing and monitoring these conditions.
Latest Patents
Svinartchouk's latest patents include groundbreaking methods for diagnosing or monitoring muscular dystrophies. One of his inventions relates to a method for prognosing, diagnosing, determining the risk, and monitoring the evolution of muscular dystrophy. This invention also evaluates the efficacy of treatments for individuals affected by muscular dystrophy. Another significant patent is a method for diagnosing muscular dystrophy, which involves detecting titin or its fragments in bodily fluids. These advancements are crucial for improving patient care and treatment outcomes.
Career Highlights
Throughout his career, Svinartchouk has worked with prominent organizations such as Genethon and Université Pierre et Marie Curie (Paris 6). His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to important research initiatives.
Collaborations
Some of Svinartchouk's notable coworkers include Jérémy Rouillon and Jérôme Denard. Their collaborative efforts have further enhanced the research and development of diagnostic methods for muscular dystrophies.
Conclusion
Fedor Svinartchouk's innovative work in the diagnosis and monitoring of muscular dystrophies has made a significant impact in the medical field. His patents and collaborations reflect his commitment to advancing healthcare solutions for patients.